Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Despite the overall improvement in life expectancy of patients living with congenital heart
disease (congenital HD), disparities in morbidity and mortality remain throughout the …

Advances in cancer therapeutics have revolutionized survival outcomes in patients with
cancer. However, cardiovascular toxicities associated with specific cancer therapeutics …

This report from the European Society of Cardiology (ESC) Atlas Project updates and
expands upon the 2021 report in presenting cardiovascular disease (CVD) statistics for the …

ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Socioeconomic disparities in cardiovascular risk factors and outcomes exist among women,
particularly those of minority racial or ethnic backgrounds. Barriers to optimal cardiovascular …

Women are under-represented as leaders of cardiovascular randomized controlled trials,
representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals …

The congenital heart care community faces a myriad of public health issues that act as
barriers toward optimum patient outcomes. In this article, we attempt to define advocacy and …

Background Clinical trials change practice in cardiology, and leading them requires
research training, mentorship, sponsorship, and networking. Women report challenges in …

Advances in cancer therapeutics have led to dramatic improvements in survival, now
inclusive of nearly 20 million patients and rising. However, cardiovascular toxicities …